About Indoco Remedies Ltd Profile

Overview 

 

Indoco Remedies Ltd. is a research-oriented pharma company with its head office in Mumbai, Maharashtra, India. Incorporated in 1947, Indoco Remedies manufactures and markets Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). The company’s geographical segments include 55-plus countries, including India, USA, Latin American and CIS countries.

The company offers products for therapeutic categories such as anti-infectives, dermatology, gastrointestinal, gynaecological, ophthal/otologicals, pain/analgesics, respiratory, stomatologicals, vitamins, minerals and nutrients.

With a wide range of international approvals in place, Indoco has emerged as a preferred partner and provider of Contract Research and Manufacturing Services (CRAMS) to customers worldwide.

As on 31st March 2016, the company had:

  • 9 manufacturing facilities – 6 for Finished Dosages and 3 for APIs
  • A well supported state-of-the-art R&D Centre with 300 scientists
  • Presence in 55 countries globally for Formulations and APIs
  • 49 products ranking among the Top 5 in their respective therapeutic categories

Indoco Remedies Ltd. is listed on both Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

 

Indoco Remedies Limited at-a-glance

 

  • Employees 5,500
  • Net Revenue (FY2015-16) ~USD 152 million

(~?1,010 crores)

  • Markets Served (countries) 55+
  • Manufacturing Facilities 9
  • ANDAs Filed (FY 2015-16) 6
  • ANDAs at Various Stages 38
  • EU CTD Dossiers 28
  • Process Patents 72 (FDF – 23, APIs – 49)
  • USFDA Approvals 3

*Source: http://www.indoco.com

Certifications

  • US-FDA
  • TGA Australia
  • MCC-South Africa
  • SUKL-Czech Republic
  • Anvisa-Brazil
  • BfArM-Germany
  • COFEPRIS-Mexico
  • UK-MHRA

 

History

 

In 1945, Goan entrepreneur Mr. Govind Ramnath Kare started Indo Continental Trading Company. Initially, the firm imported pharmaceutical formulations from Europe and sold them in Western India.

In 1947 (post-independence), the newly formed Government in its bid to encourage indigenous manufacturing of medicines barred import of several formulations. Mr. GR Kare decided to take on the manufacturing of pharmaceuticals.

On 23rd August 1947, a week after India's independence, a new Company was instituted to manufacture and sell pharmaceutical formulations, and Indo Continental Trading Company became Indoco Remedies Limited.

 

Milestones

 

  • 1993: DSIR recognizes R&D Centre

  • 1997: Initiation of production in Goa Plant I

  • 1999:

  • Establishes new Corporate Office at Indoco House

  • Acquires Warren and makes presence in Ophthalmic & Dental Segments

  • 2002: Launches state-of-the-art sterile facility, Plant II commissioned at Verna Goa

  • 2003:

      • Begins domestic marketing in the lifestyle segment

      • Signs first contract for Dossier Development with a European company

      • Begins to export to regulated markets

      • UK-MHRA approves Solid Dosage facility at Plant I

  • 2004:

      • Jumps 5 ranks in two years in the ORG-IMS Retail Audit

      • Files 4 patent applications

      • Acquires Karvol brand from Solvay Pharmaceuticals Pvt. Ltd.

      • Signs first contract for Development services with a US Company

  • 2005:

      • Lists company shares on BSE and NSE

      • Doubles tablet capacity in existing UK-MHRA approved plant

      • Signs development contracts for injectable products with a US company

      • Files first ANDA based on Exhibit batches manufactured in Goa sterile facility

  • 2006:

      • Re-inspects Solid Dosage facility at Goa Plant I & receives UK-MHRA approval

      • Opens and makes functional new R&D Centre at Rabale, near Mumbai

      • Commences liquid manufacturing facility at Baddi, Himachal Pradesh

      • Files 2 ANDAs with USFDA

      • Signs contract for supply of 18 generic products to Germany

      • US-FDA approves Ophthalmic facility, Plant-II in GOA

      • Launches Surge – a specialty marketing division

      • Acquires LaNOVA Chem Pvt. Ltd. along with its new API manufacturing facility of international standards

      • Receives approval from Darmstadt-Germany for Goa facility for Solid Dosage manufacturing

      • Receives approval from UK-MHRA for Creams & Ointments facility

  • 2007:

      • Launches two specialty marketing divisions – Warren-Excel and Spera

      • Commences exports to the US markets

      • Receives approval from ANVISA (Brazil) for Solid Dosage facility at GOA Plant I

  • 2008:

      • Receives MCC (South Africa) approval for Solid Dosage facility at GOA Plant I and for the Sterile facility at Goa Plant II

      • Ships Diclofenac Ophthalmic solution to the USA against approved ANDA

      • Receives TGA (Australia) approval for Solid Dosage, Liquid Orals and Creams & Ointments Dosage forms at GOA Plant I

      • Receives Silver Award for the Solid Dosage Forms and Externals Facility at Goa Plant I

      • Receives Gold Award for the Sterile Facility at Goa Plant II

      • Receives IDMA Quality Excellence Awards 2008

  • 2009:

      • Successful audit of Slovenia for Sterile Facility at Goa Plant II for the Injections Area

      • Export sales surge to ?1 billion in FY 2008-9

      • Receives UK-MHRA approval for Solid Oral Dosage forms at Baddi Plant

  • 2010:

      • Licenses out technology to Watson Pharmaceuticals Inc. USA. under profit sharing agreement

      • Teams up with ASPEN, South Africa for licensing intellectual property (dossiers) for marketing products in 30 emerging markets including SA, Brazil, Mexico, Venezuela, Russia & Australia

  • 2011:

      • Receives Silver Quality Excellence Award for Sterile Manufacturing Facility in Goa and Solid Dosages Facility in Baddi (Himachal\Pradesh) at IDMA's Golden Jubilee celebrations

  • 2012:

  • Signs agreement with DSM, a €9 billion company, to market and sell APIs

  • Receives Innovation in Quality Award at CPhI Pharma Awards

  • 2014:

  • Receives approval from the US-FDA for Sterile (Plant II) and Solid Dosages (Plant III) facilities in Goa

  • Receives IDMA Best Patent Award for Tazarotene & Adapalene

  • 2015:

  • Receives Indoco IDMA Patent Appreciation Award for Betaxolol

  • 2016:

  • Receives IDMA Best Patent Award for Three International Patents

  • Achieves a milestone of ?1000 crores

  • Acquires Oral Solid Dosage manufacturing facility in Baddi from Micro Labs Ltd., Bangalore

  • Allopurinol ANDA receives USFDA approval

  • Climbs 187 ranks up (Fortune India)

  • Receives USFDA approval for solid dosages Plant I in Goa

  • Receives the 'Best Patent Award' by PHARMEXCIL in the Bulk Drugs / API category

  • 2017:

      • Receives patent grant for Linezolid & Brinzolamide (FDFs) from United States Patent and Trademark Office (USPTO)

      • Receives the IDMA Best Patent Award for four API Process Patents

      • Receives UKMHRA approval for solid dosages Plant I in Goa

 

BOARD OF DIRECTORS

 

  • Chairman Mr. Suresh G. Kare
  • Managing Director Ms. Aditi Kare Panandikar
  • Jt. Managing Director Mr. Sundeep V. Bambolkar
  • Independent Director Mr. D. M. Gavaskar
  • Independent Director Mr. Sharad P. Upasani
  • Independent Director Mr. Rajiv P. Kakodkar
  • Independent Director Dr. Anil M. Naik
  • Non-Executive Director Dr. Anand Nadkarni

 

CONTACTS

 

REGISTERED OFFICE

Indoco House, 166 CST Road,

Kalina, Santacruz (East)

Mumbai-400098

Maharashtra, India

Website: www.indoco.com

Tel: +91-22-2654 1851 to 2654 1855

Email: compliance.officer@indoco.com

 



Comment!
 
 






* Indicates mandatory field.
Please wait while comments are being sent...